Oreofe Olukemi Odejide, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hospice Care | 15 | 2023 | 671 | 3.900 |
Why?
|
Hematologic Neoplasms | 12 | 2023 | 1820 | 2.830 |
Why?
|
Terminal Care | 12 | 2021 | 1688 | 2.250 |
Why?
|
Hospices | 4 | 2023 | 264 | 2.140 |
Why?
|
Palliative Care | 8 | 2023 | 3478 | 0.960 |
Why?
|
Bone Marrow Examination | 3 | 2016 | 157 | 0.950 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 4 | 2023 | 1377 | 0.920 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2022 | 1379 | 0.690 |
Why?
|
Specimen Handling | 2 | 2014 | 692 | 0.660 |
Why?
|
Lymphoma, Mantle-Cell | 2 | 2020 | 233 | 0.590 |
Why?
|
Bone Marrow Cells | 2 | 2014 | 2513 | 0.530 |
Why?
|
Medicare | 7 | 2023 | 6532 | 0.480 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 2013 | 35 | 0.480 |
Why?
|
Neoplasms | 8 | 2023 | 21596 | 0.470 |
Why?
|
Multiple Myeloma | 2 | 2022 | 5169 | 0.420 |
Why?
|
Immunotherapy, Adoptive | 1 | 2020 | 1255 | 0.410 |
Why?
|
Quality of Life | 8 | 2023 | 12730 | 0.400 |
Why?
|
Hematopoietic Stem Cell Transplantation | 8 | 2023 | 5425 | 0.400 |
Why?
|
Lymphoma, T-Cell | 1 | 2013 | 299 | 0.390 |
Why?
|
Lymphoma | 4 | 2022 | 1873 | 0.350 |
Why?
|
Cause of Death | 2 | 2017 | 3571 | 0.350 |
Why?
|
Medical Oncology | 3 | 2017 | 2235 | 0.340 |
Why?
|
Physician-Patient Relations | 3 | 2023 | 3215 | 0.340 |
Why?
|
Hodgkin Disease | 3 | 2022 | 1413 | 0.330 |
Why?
|
Lymphoma, B-Cell | 1 | 2015 | 930 | 0.330 |
Why?
|
Health Services Accessibility | 2 | 2016 | 5133 | 0.330 |
Why?
|
Caregivers | 6 | 2023 | 2074 | 0.330 |
Why?
|
Communication | 2 | 2019 | 3728 | 0.310 |
Why?
|
Radiotherapy | 1 | 2014 | 1525 | 0.300 |
Why?
|
Quality Indicators, Health Care | 2 | 2016 | 1831 | 0.290 |
Why?
|
Prognosis | 7 | 2023 | 29010 | 0.270 |
Why?
|
Isoquinolines | 3 | 2021 | 368 | 0.250 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 11472 | 0.230 |
Why?
|
SEER Program | 3 | 2018 | 1507 | 0.230 |
Why?
|
Humans | 52 | 2023 | 742088 | 0.230 |
Why?
|
Patients | 2 | 2023 | 892 | 0.220 |
Why?
|
Focus Groups | 2 | 2020 | 1320 | 0.220 |
Why?
|
Blood Transfusion | 2 | 2020 | 1296 | 0.210 |
Why?
|
Transplantation, Autologous | 6 | 2023 | 2123 | 0.210 |
Why?
|
Aged | 22 | 2023 | 162944 | 0.210 |
Why?
|
Depression | 1 | 2022 | 7733 | 0.210 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2023 | 134 | 0.200 |
Why?
|
Leukemia | 2 | 2022 | 1507 | 0.200 |
Why?
|
Purines | 2 | 2021 | 593 | 0.200 |
Why?
|
United States | 10 | 2023 | 69693 | 0.190 |
Why?
|
Quality of Health Care | 4 | 2018 | 4369 | 0.190 |
Why?
|
Male | 28 | 2023 | 349538 | 0.190 |
Why?
|
Female | 30 | 2023 | 379592 | 0.180 |
Why?
|
Attitude to Death | 1 | 2023 | 382 | 0.180 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 1596 | 0.180 |
Why?
|
Lymphoma, Follicular | 1 | 2023 | 435 | 0.170 |
Why?
|
Factor Analysis, Statistical | 1 | 2021 | 975 | 0.160 |
Why?
|
Multivariate Analysis | 4 | 2017 | 12242 | 0.160 |
Why?
|
Bereavement | 1 | 2022 | 273 | 0.160 |
Why?
|
Cyclophosphamide | 3 | 2021 | 2236 | 0.140 |
Why?
|
Myelodysplastic Syndromes | 2 | 2016 | 1351 | 0.130 |
Why?
|
Blue Cross Blue Shield Insurance Plans | 1 | 2016 | 94 | 0.130 |
Why?
|
Goals | 1 | 2021 | 705 | 0.130 |
Why?
|
Aged, 80 and over | 10 | 2022 | 57683 | 0.130 |
Why?
|
Tissue Banks | 1 | 2016 | 183 | 0.130 |
Why?
|
Middle Aged | 17 | 2023 | 213127 | 0.130 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2017 | 341 | 0.120 |
Why?
|
Adult | 14 | 2023 | 213712 | 0.120 |
Why?
|
Proportional Hazards Models | 3 | 2023 | 12344 | 0.120 |
Why?
|
Patient Care Planning | 1 | 2019 | 921 | 0.120 |
Why?
|
Autoimmunity | 1 | 2021 | 1348 | 0.120 |
Why?
|
Antineoplastic Agents | 6 | 2023 | 13655 | 0.110 |
Why?
|
Cancer Care Facilities | 1 | 2016 | 401 | 0.110 |
Why?
|
T-Lymphocytes | 3 | 2023 | 10163 | 0.110 |
Why?
|
Hematology | 1 | 2016 | 219 | 0.110 |
Why?
|
Research | 1 | 2021 | 1999 | 0.110 |
Why?
|
Vincristine | 1 | 2014 | 1036 | 0.100 |
Why?
|
Mutation | 2 | 2013 | 29717 | 0.100 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 24913 | 0.100 |
Why?
|
Logistic Models | 3 | 2016 | 13403 | 0.100 |
Why?
|
Anemia, Aplastic | 1 | 2013 | 226 | 0.100 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2016 | 3915 | 0.090 |
Why?
|
Anxiety Disorders | 1 | 2022 | 2684 | 0.090 |
Why?
|
Stem Cell Transplantation | 3 | 2023 | 1618 | 0.090 |
Why?
|
Vidarabine | 2 | 2021 | 345 | 0.090 |
Why?
|
Health Care Surveys | 1 | 2017 | 2451 | 0.090 |
Why?
|
Prednisone | 1 | 2014 | 1567 | 0.090 |
Why?
|
Life Expectancy | 1 | 2016 | 1183 | 0.080 |
Why?
|
Renal Dialysis | 1 | 2018 | 1780 | 0.080 |
Why?
|
Intensive Care Units | 2 | 2019 | 3679 | 0.080 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2016 | 974 | 0.080 |
Why?
|
Critical Care | 1 | 2021 | 2640 | 0.080 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 1093 | 0.080 |
Why?
|
Analysis of Variance | 1 | 2017 | 6365 | 0.080 |
Why?
|
Cohort Studies | 4 | 2016 | 40450 | 0.080 |
Why?
|
Patient Admission | 1 | 2016 | 1380 | 0.080 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 4929 | 0.080 |
Why?
|
Neoplasm, Residual | 2 | 2023 | 974 | 0.080 |
Why?
|
Intubation, Intratracheal | 1 | 2016 | 1357 | 0.080 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2016 | 3557 | 0.080 |
Why?
|
Doxorubicin | 1 | 2014 | 2215 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2023 | 9185 | 0.080 |
Why?
|
Information Dissemination | 1 | 2016 | 1100 | 0.080 |
Why?
|
Patient Transfer | 1 | 2014 | 760 | 0.080 |
Why?
|
Anxiety | 1 | 2022 | 4279 | 0.070 |
Why?
|
Bone Marrow | 2 | 2020 | 2941 | 0.070 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 3014 | 0.070 |
Why?
|
Critical Illness | 2 | 2017 | 2665 | 0.070 |
Why?
|
Continuity of Patient Care | 1 | 2014 | 1048 | 0.070 |
Why?
|
Age Factors | 4 | 2020 | 18355 | 0.070 |
Why?
|
Gene Frequency | 1 | 2013 | 3587 | 0.070 |
Why?
|
Attitude of Health Personnel | 2 | 2021 | 3839 | 0.070 |
Why?
|
Neoplasm Staging | 3 | 2020 | 11001 | 0.070 |
Why?
|
Social Class | 1 | 2015 | 1995 | 0.070 |
Why?
|
Odds Ratio | 2 | 2016 | 9846 | 0.070 |
Why?
|
Leukocytes, Mononuclear | 2 | 2023 | 1835 | 0.070 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2012 | 806 | 0.070 |
Why?
|
Pyrroles | 1 | 2012 | 1143 | 0.070 |
Why?
|
Health Expenditures | 1 | 2018 | 2346 | 0.060 |
Why?
|
DNA Mutational Analysis | 1 | 2013 | 4187 | 0.060 |
Why?
|
Antibodies, Monoclonal | 2 | 2023 | 9274 | 0.060 |
Why?
|
Cytarabine | 2 | 2020 | 684 | 0.060 |
Why?
|
Sex Factors | 2 | 2016 | 10392 | 0.060 |
Why?
|
Time Factors | 2 | 2016 | 40054 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7770 | 0.060 |
Why?
|
Indoles | 1 | 2012 | 1834 | 0.060 |
Why?
|
Mental Disorders | 1 | 2023 | 6587 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 1 | 2014 | 6534 | 0.060 |
Why?
|
Sepsis | 1 | 2017 | 2589 | 0.060 |
Why?
|
Ontario | 1 | 2023 | 381 | 0.050 |
Why?
|
Angiogenesis Inhibitors | 1 | 2012 | 2038 | 0.050 |
Why?
|
B-Lymphocytes | 1 | 2014 | 4664 | 0.050 |
Why?
|
Comorbidity | 1 | 2015 | 10372 | 0.050 |
Why?
|
Disease-Free Survival | 2 | 2023 | 6891 | 0.050 |
Why?
|
Young Adult | 3 | 2022 | 56350 | 0.050 |
Why?
|
Hospitalization | 1 | 2019 | 10232 | 0.040 |
Why?
|
Advance Directives | 1 | 2021 | 245 | 0.040 |
Why?
|
Adolescent | 3 | 2023 | 85649 | 0.040 |
Why?
|
Thyroid Neoplasms | 1 | 2012 | 2274 | 0.040 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2012 | 3497 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2012 | 4249 | 0.040 |
Why?
|
Uncertainty | 1 | 2021 | 725 | 0.030 |
Why?
|
Child | 2 | 2022 | 77478 | 0.030 |
Why?
|
Enterococcus faecalis | 1 | 2017 | 251 | 0.030 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 246 | 0.030 |
Why?
|
Cytogenetics | 1 | 2016 | 203 | 0.030 |
Why?
|
Retrospective Studies | 6 | 2021 | 77098 | 0.030 |
Why?
|
Treatment Outcome | 3 | 2020 | 62966 | 0.030 |
Why?
|
Longevity | 1 | 2022 | 1069 | 0.030 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 222 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1780 | 0.030 |
Why?
|
Data Collection | 1 | 2023 | 3339 | 0.030 |
Why?
|
Survival Analysis | 2 | 2018 | 10248 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 755 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 380 | 0.030 |
Why?
|
Hematinics | 1 | 2016 | 281 | 0.030 |
Why?
|
Antigens, CD | 2 | 2014 | 4024 | 0.030 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2017 | 657 | 0.030 |
Why?
|
Colorectal Neoplasms | 1 | 2012 | 6754 | 0.030 |
Why?
|
Milk, Human | 1 | 2017 | 490 | 0.030 |
Why?
|
Daunorubicin | 1 | 2012 | 149 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2019 | 1269 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2085 | 0.030 |
Why?
|
Ilium | 1 | 2012 | 155 | 0.030 |
Why?
|
Sternum | 1 | 2012 | 175 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1875 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2425 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3564 | 0.020 |
Why?
|
Organoplatinum Compounds | 1 | 2012 | 408 | 0.020 |
Why?
|
Clone Cells | 1 | 2014 | 1692 | 0.020 |
Why?
|
Leucovorin | 1 | 2012 | 624 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2021 | 5519 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2016 | 1679 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2014 | 1866 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2014 | 1184 | 0.020 |
Why?
|
Translocation, Genetic | 1 | 2014 | 1417 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2012 | 824 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4438 | 0.020 |
Why?
|
Immunotherapy | 1 | 2023 | 4414 | 0.020 |
Why?
|
Infant, Premature | 1 | 2017 | 2041 | 0.020 |
Why?
|
Fluorouracil | 1 | 2012 | 1615 | 0.020 |
Why?
|
Safety | 1 | 2012 | 1185 | 0.020 |
Why?
|
Iron | 1 | 2016 | 1773 | 0.020 |
Why?
|
Pain | 1 | 2022 | 4961 | 0.020 |
Why?
|
Income | 1 | 2016 | 1904 | 0.020 |
Why?
|
Cell Lineage | 1 | 2016 | 2504 | 0.020 |
Why?
|
Remission Induction | 1 | 2012 | 2384 | 0.020 |
Why?
|
Self Report | 1 | 2018 | 3548 | 0.020 |
Why?
|
Cytokines | 1 | 2021 | 7317 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1790 | 0.020 |
Why?
|
Piperazines | 1 | 2016 | 2488 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 2723 | 0.020 |
Why?
|
Patient Care Team | 1 | 2016 | 2527 | 0.020 |
Why?
|
Prevalence | 1 | 2021 | 15194 | 0.010 |
Why?
|
Internet | 1 | 2016 | 3062 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3691 | 0.010 |
Why?
|
Massachusetts | 1 | 2016 | 8662 | 0.010 |
Why?
|
Health Status | 1 | 2016 | 4030 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10578 | 0.010 |
Why?
|
Gene Expression | 1 | 2014 | 7790 | 0.010 |
Why?
|
Quality Improvement | 1 | 2016 | 3738 | 0.010 |
Why?
|
Databases, Factual | 1 | 2016 | 7716 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 5979 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2016 | 9410 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 9941 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2017 | 7153 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2014 | 10472 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16331 | 0.010 |
Why?
|
Survival Rate | 1 | 2012 | 12773 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2017 | 25575 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2012 | 21719 | 0.010 |
Why?
|
Risk Assessment | 1 | 2016 | 23320 | 0.010 |
Why?
|
Risk Factors | 1 | 2021 | 72145 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2012 | 39004 | 0.010 |
Why?
|
Child, Preschool | 1 | 2013 | 40955 | 0.010 |
Why?
|
Mice | 1 | 2016 | 81045 | 0.010 |
Why?
|
Animals | 1 | 2016 | 168561 | 0.000 |
Why?
|